Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Share-based Compensation (2023 - 2026)

ArriVent BioPharma has reported Share-based Compensation over the past 4 years, most recently at $5.5 million for Q1 2026.

  • Quarterly results put Share-based Compensation at $5.5 million for Q1 2026, up 141.52% from a year ago — trailing twelve months through Mar 2026 was $15.7 million (up 224.21% YoY), and the annual figure for FY2025 was $12.5 million, up 290.27%.
  • Share-based Compensation reached $5.5 million in Q1 2026 per AVBP's latest filing, up from $3.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $216.0 million in Q3 2023 and bottomed at $166000.0 in Q1 2023.
  • Median Share-based Compensation over the past 4 years was $2.3 million (2025), compared with a mean of $33.1 million.
  • The largest annual shift saw Share-based Compensation tumbled 99.6% in 2024 before it surged 332.25% in 2025.
  • Over 4 years, Share-based Compensation stood at $319000.0 in 2023, then soared by 198.12% to $951000.0 in 2024, then skyrocketed by 238.8% to $3.2 million in 2025, then surged by 70.24% to $5.5 million in 2026.
  • Business Quant data shows Share-based Compensation for AVBP at $5.5 million in Q1 2026, $3.2 million in Q4 2025, and $3.7 million in Q3 2025.